<DOC>
	<DOCNO>NCT02118077</DOCNO>
	<brief_summary>Compare effect G17DT placebo survival subject advance pancreatic cancer .</brief_summary>
	<brief_title>Sequential Trial G17DT Treatment Advanced Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gastrins</mesh_term>
	<criteria>Subjects histologically cytologically confirm diagnosis pancreatic carcinoma , eligible tumor resection curative intent ( i.e. , Stage II , III , IV disease ) Male female subject 18 year age Subjects life expectancy least 2 month KPS score ≥60 % Written inform consent Previous , concomitant , anticipate use ( Week 12 ) chemotherapy , radiotherapy , immunotherapy , anticancer therapy Previous ( 4 week study ) , concomitant , anticipate use ( Week 12 ) immunosuppressant . However , systemic [ i.e. , oral inject ] corticosteroid , previous use concomitant use study entry prohibit , introduction course study permit . ) History malignant tumor within previous 5 year , except nonmelanomatous skin cancer , situ carcinoma uterine cervix Known immunodeficiency Females pregnant , plan become pregnant , lactate ( Women , opinion investigator , childbearing potential negative pregnancy test study drug administration . ) Subjects take part another study involve investigational license drug device 3 month precede enrollment Week 12 study Previous G17DT treatment Hematological indicator follow : Hemoglobin &lt; 9.5 g/dL Neutrophils &lt; 2.0 × 109/L Platelets &lt; 100 × 109/L Any condition circumstance might follow result : Worsen subject participate study Reduce subject 's ability comply protocol Confound interpretation study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>